|
Early prediction of clinical outcomes in resected stage II and III colorectal cancer (CRC) through deep sequencing of circulating tumor DNA (ctDNA). |
|
|
Stock and Other Ownership Interests - CAPP Medical; CiberMed; Quanticel Pharma |
Consulting or Advisory Role - Quanticel Pharma; Roche |
Research Funding - Varian Medical Systems |
Patents, Royalties, Other Intellectual Property - Patent filings on ctDNA detection assigned to Stanford University (Inst); Patent filings on tumor treatment resistance mechanisms assigned to Stanford University (Inst) |
Travel, Accommodations, Expenses - Roche; Varian Medical Systems |
|
|
Leadership - Lymphoma Research Foundation |
Stock and Other Ownership Interests - CAPP Medical; CiberMed |
|
Consulting or Advisory Role - Celgene; Gilead Sciences; Roche/Genentech |
Research Funding - Celgene |
Patents, Royalties, Other Intellectual Property - Patent filings on ctDNA detection, assigned to Stanford University. (Inst) |
Travel, Accommodations, Expenses - Gilead Sciences; Roche |
|
|
No Relationships to Disclose |
|
|
|
Travel, Accommodations, Expenses - Roche |
|
|
|
|
|
|
Stock and Other Ownership Interests - Clovis Oncology; Exact Sciences; Johnson & Johnson; Roche |
Patents, Royalties, Other Intellectual Property - Affymetrix; Johnson & Johnson; Metabolex |
|
|
|
Stock and Other Ownership Interests - Roche |
Patents, Royalties, Other Intellectual Property - Roche |
|
|
|
|
|
Stock and Other Ownership Interests - CAPP Medical |
Consulting or Advisory Role - Roche |
Patents, Royalties, Other Intellectual Property - Patents pending and royalties received for inventions developed at Stanford University. |
|
|
|
|
|
|
Patents, Royalties, Other Intellectual Property - Harvard Medical School; Roche (Inst) |
|
|
|
|
|
|
|
Stock and Other Ownership Interests - Roche |
|
|
|
Stock and Other Ownership Interests - Roche |
Patents, Royalties, Other Intellectual Property - Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |